ARGENX SE news, videos and press releases
For more news please use our advanced search feature.
ARGENX SE - More news...
ARGENX SE - More news...
- argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
- argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
- argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
- argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
- argenx to Present at TD Cowen 45th Annual Healthcare Conference
- argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
- argenx Highlights 2025 Strategic Priorities
- argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
- argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
- argenx to Present at Upcoming Investor Conferences
- argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
- argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
- argenx to Participate at Upcoming Investor Conferences
- argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
- argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
- argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
- argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
- argenx to Present at Upcoming Investor Conferences
- argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
- argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
- argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
- argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
- argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
- argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
- argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
- argenx Reports First Quarter 2024 Financial Results and Provides Business Update
- argenx announces results of Annual General Meeting of Shareholders
- argenx to Present at BofA Securities 2024 Health Care Conference
- argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
